Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common supplement calm Kids' mood swings? new trial investigates

NCT ID NCT07323446

Not yet recruiting Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether N-Acetylcysteine (NAC), a supplement, can help children ages 6-12 who struggle with emotional dysregulation (severe mood swings, irritability). Half of the 80 children with emotional dysregulation will receive NAC daily for 8 weeks, while the other half get a placebo. Brain scans before and after treatment will look for changes. The goal is to see if NAC can reduce symptoms like mania and depression, offering a potential new option for families.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
N-Acetylcysteine (NAC)
What this could lead to
If it works, this could point toward a safe, over-the-counter supplement option to help children with emotional dysregulation, reducing mood swings and irritability.
What could go wrong
This is a very early (Phase 1) trial with only 120 participants, so results may not apply broadly. NAC may not improve symptoms, and side effects are not yet well understood in children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EMOTIONAL DYSREGULATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EMOTIONAL DYSREGULATION

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

    Contact Email: •••••@•••••

  • Massachusetts Institute of Technology

    Cambridge, Massachusetts, 02139, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.